Allogene Therapeutics
Roberto Sessa is a Principal Scientist at Allogene Therapeutics, where since October 2018, responsibilities include the development of the CART process and the provision of technical expertise for optimizing CART manufacturing. Previous roles include Senior Scientist at Allogene Therapeutics focused on early process development of CAR-T cells, Scientist at Pfizer collaborating on allogenic CAR-T therapies, and Contractor Scientist at Celgene conducting in vitro assays for autoimmune disease research. Further academic experience encompasses post-doctoral positions at UC Berkeley and University California San Francisco, with significant research on lymphatic vasculature and microRNAs in vascular biology. Roberto Sessa holds a Ph.D. from the IRCC - Institute for Cancer Research and Treatment and a Master’s Degree in Industrial Biotechnology from Università degli Studi di Torino, along with a high school diploma in Chemistry.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.